Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y, Hosomi Y, Oshita F, Okamoto H, Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, Sakamoto T, Miura Y, Yomota M, Satoh A, Kunitoh H, Sakamaki K, Shibuya M, Watanabe K. Takagi Y, et al. Among authors: hosomi y. BMC Cancer. 2015 Oct 19;15:740. doi: 10.1186/s12885-015-1756-1. BMC Cancer. 2015. PMID: 26481215 Free PMC article. Clinical Trial.
Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
Takagi Y, Hosomi Y, Nagamata M, Watanabe K, Takahashi S, Nakahara Y, Yomota M, Sunami K, Okuma Y, Shimokawa T, Okamura T. Takagi Y, et al. Among authors: hosomi y. Cancer Chemother Pharmacol. 2016 Mar;77(3):559-64. doi: 10.1007/s00280-015-2954-x. Epub 2016 Jan 28. Cancer Chemother Pharmacol. 2016. PMID: 26821156 Clinical Trial.
Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1.
Nakahara Y, Takagi Y, Hosomi Y, Kagei A, Yamamoto T, Sawada T, Yomota M, Okuma Y, Mikura S, Okamura T. Nakahara Y, et al. Among authors: hosomi y. Onco Targets Ther. 2016 Aug 24;9:5287-95. doi: 10.2147/OTT.S105976. eCollection 2016. Onco Targets Ther. 2016. PMID: 27601920 Free PMC article.
201 results